KRd Maintenance Improves PFS in Transplant-Eligible Multiple Myeloma

home / oncclub / krd-maintenance-improves-pfs-in-transplant-eligible-multiple-myeloma

Andrzej Jakubowiak, MD, PhD, discusses interim data from the phase 3 ATLAS trial (NCT02659293), which evaluated lenalidomide (Revlimid) plus carfilzomib (Kyprolis) and dexamethasone vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who had previously received induction therapy and autologous stem cell transplant.